FDA Approves Keytruda (Pembrolizumab) for Any Tumor with Specific Genetic Change



The US Food and Drug Administration (FDA) has expanded the approval of the immunotherapy drug Keytruda (pembrolizumab) to include tumors with a specific genetic change regardless of cancer type.



Source link

Comments are closed.